By Dr Nicola Davies
One of the latest developments in medicine is the advent of cell and gene therapies (CGTs). Cell therapies include cellular immunotherapies, cancer vaccines, and stem cells. Gene therapies are designed to modify the expression of specific genes or alter the biological properties of cells for the treatment of diseases.
CGT products are regulated by the US Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER). Currently, there are 22 CGTs approved in the US.1 Among these, recently approved products include Gilead Sciences’ (Nasdaq: GILD) subsidiary Kite Pharma’s brexucabtagene autoleucel (Tecartus), a T cell immunotherapy for mantle cell lymphoma and acute lymphoblastic leukemia,2 and Bristol Myers Squibb (NYSE: BMY) unit Celgene’s idecabtagene vicleucel (Abecma), a cell-based gene therapy for multiple myeloma.3
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze